Literature DB >> 2956327

The murine lymphocyte receptor for IgE. V. Biosynthesis, transport, and maturation of the B cell Fc epsilon receptor.

A D Keegan, D H Conrad.   

Abstract

The post-translational processing and maturation of the receptor for IgE (Fc epsilon R) on murine hybridoma B cells were studied to determine the carbohydrate content and the importance of processing events in cell surface expression and ligand (IgE) binding ability. Endo and exoglycosidase treatment demonstrated that the mature receptor is composed of two to three complex-type N-linked oligosaccharides and contains sialic acid. Pulse-chase experiments indicated that the receptor is synthesized as a 44,000 dalton precursor that begins to be processed by 1 hr to the mature 49,000 dalton form, and the latter is expressed at the cell surface by 2 hr. It was determined that the processing included the conversion of N-linked oligosaccharides to the complex type as well as an additional processing event, because in the presence of tunicamycin, the receptor is synthesized as a 36,000 dalton precursor that is processed to a 38,000 dalton species. Analysis of the effects of tunicamycin treatment and endo F digestion on soluble Fc epsilon R isolated from cell supernatants demonstrated the existence of several m.w. species of Fc epsilon R fragments, and indicated that only the higher m.w. fragments were N-glycosylated. The use of several inhibitors of the N-linked carbohydrate processing pathway demonstrated that the addition of core N-linked side-chains, but not their processing to the complex type, is required for cell surface expression of Fc epsilon R. Also, processing of N-linked carbohydrate is not required for ligand binding activity. Finally, IgE affinity chromatography indicated that the 49,000 and 38,000 dalton (tunicamycin) Fc epsilon R bind IgE more effectively than their precursor forms, 44,000 and 36,000 daltons, respectively, indicating that a processing event independent of N-linked glycosylation is necessary for optimal ligand binding activity.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 2956327

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  8 in total

1.  CD23 Sheddase A disintegrin and metalloproteinase 10 (ADAM10) is also required for CD23 sorting into B cell-derived exosomes.

Authors:  Joel A Mathews; David R Gibb; Bing-Hung Chen; Peggy Scherle; Daniel H Conrad
Journal:  J Biol Chem       Date:  2010-09-28       Impact factor: 5.157

Review 2.  Low affinity IgE receptors (Fc epsilon RII).

Authors:  D H Conrad
Journal:  Clin Rev Allergy       Date:  1989

Review 3.  The receptor for the Fc region of IgE.

Authors:  A D Keegan; D H Conrad
Journal:  Springer Semin Immunopathol       Date:  1990

4.  Defective expression of CD23 and autocrine growth-stimulation in Epstein-Barr virus (EBV)-transformed B cells from patients with Wiskott-Aldrich syndrome (WAS).

Authors:  H U Simon; E A Higgins; M Demetriou; A Datti; K A Siminovitch; J W Dennis
Journal:  Clin Exp Immunol       Date:  1993-01       Impact factor: 4.330

5.  Native and recombinant soluble CD23 fragments with IgE suppressive activity.

Authors:  M Sarfati; B Bettler; M Letellier; S Fournier; M Rubio-Trujillo; H Hofstetter; G Delespesse
Journal:  Immunology       Date:  1992-08       Impact factor: 7.397

6.  Adrenergic regulation of IgE involves modulation of CD23 and ADAM10 expression on exosomes.

Authors:  Caroline J Padro; Todd M Shawler; Matthew G Gormley; Virginia M Sanders
Journal:  J Immunol       Date:  2013-10-18       Impact factor: 5.422

7.  Molecular structure and expression of the murine lymphocyte low-affinity receptor for IgE (Fc epsilon RII).

Authors:  B Bettler; H Hofstetter; M Rao; W M Yokoyama; F Kilchherr; D H Conrad
Journal:  Proc Natl Acad Sci U S A       Date:  1989-10       Impact factor: 11.205

Review 8.  Tuning the Cytokine Responses: An Update on Interleukin (IL)-4 and IL-13 Receptor Complexes.

Authors:  Ilkka S Junttila
Journal:  Front Immunol       Date:  2018-06-07       Impact factor: 7.561

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.